Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California and currently employs 1,313 full-time employees. The company went IPO on 2016-09-28. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Mr. Ming Hsieh is the Chairman of the Board of Fulgent Genetics Inc, joining the firm since 2016.
What is the price performance of FLGT stock?
The current price of FLGT is $15.85, it has decreased 0.68% in the last trading day.
What are the primary business themes or industries for Fulgent Genetics Inc?
Fulgent Genetics Inc belongs to Health Care industry and the sector is Health Care
What is Fulgent Genetics Inc market cap?
Fulgent Genetics Inc's current market cap is $471.5M
Is Fulgent Genetics Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Fulgent Genetics Inc, including 2 strong buy, 5 buy, 2 hold, 0 sell, and 2 strong sell